Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma

July 18, 2024 updated by: Cosmetique Active International

Evaluation of the Efficacy of the Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma

This 6 month, comparative study assesses the benefit of a dermocosmetic regimen (Serum B3 + B3 retinol night cream) for 6 months compared to hydroquinone 4% (the gold standard in hyperpigmentation) followed by the dermocosmetic regimen for 3 months or the Kligman Trio for 3 months followed by the dermocosmetic regimen for 3 months in adult women with melasma on the face.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Study objective

  1. Assessing the antipigmenting efficacy of the routine (serum B3 + B3 retinol night cream) in women with melasma.
  2. Evaluation of Kligman Trio (KT) (Vitacid Plus) compared to the routine (serum B3 + B3 retinol night cream)
  3. Evaluation of Hydroquinone 4% (HQ 4%) compared to the routine (serum B3 + B3 retinol night cream).
  4. Assessment of the routine maintenance with SERUM B3 + retinol B3 night cream after 3 months of use of Klingman Trio (KT)(Vitacid plus) and HQ4%

Primary endpoint:

o Improvement of mMASI and MASI

Secondary endpoints:

  • Improvement of Physician Global Assessment IGA for melasma
  • Improvements on clinical parameters such as fine lines, skin tone, radiance, skin texture and skin elasticity evaluated by the investigator.
  • Global efficacy by the subject and by the investigator (Physician's Global assessment)
  • Global tolerance
  • Safety
  • Cosmetic acceptability
  • Improvement of Quality of life (MelasQOL)
  • Exposome questionnaire
  • Questionnaire on hormonal status
  • Improvement of the morphological and structural characteristics of ageing skin - By confocal microscopy (15 subjects per subgroup)
  • Clinical scoring: hyperpigmentation scale
  • Standard facial pictures with Colorface®
  • Chromameter® measurements (target lesion assessment compared to non lesional surrounding skin)
  • Tewameter® measurements
  • Corneometer® measurements

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
150

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Brazil
      • Rio de Janeiro, Brazil
        • CIDP
        • Contact:
          • Alessandro NASCIMENTO
        • Principal Investigator:
          • Renato Moura, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18-65 years
  • Phototype II-V
  • 50% with sensitive skin (declarative);
  • Subjects should be affected by well defined symmetrical (on both sides of the face) epidermal melasma (clinically diagnosed under Wood's light examination) lasting since more than a year

Exclusion Criteria:

  • Subjects under topical or systemic retinoids;
  • Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion;
  • Subjects under systemic immunosuppressants and considered immune compromised
  • Subjects under active treatment of melasma (including topicals or procedures) within the last 3 months
  • Pregnant women and/or breastfeeding women
  • Subjects with a recent change in contraception (since less than 6 months);
  • Subjects known allergy to any component of tested product;
  • Subjects not presenting with the conditions needed to comply with the protocol;
  • Subjects without any other dermatological conditions on the face
  • Subject under menopause phase with hormonal replace therapy
  • Subjects in the initial phase, change or discontinuation of hormonal treatment (estroprogesterone, cyproteron acetate, androgenic...) in the last 3 months;
  • Subjects currently using any medication, which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.
  • Subjects unable to give their informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group 1
dermocosmetic regimen consisting in Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream (all Vichy Laboratoires, France) for 6 months + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+
Other: Liftactiv® B3 Serum
In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
Other: Liftactiv® B3 retinol night cream
In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
Other: Sunscreen UVAage® Inter SPF 50+
twice daily (morning and beginning of the afternoon)
Other: Mineral 89 cream
2 drops in the morning before sunscreen application for 6 months
Active Comparator: Group 2
hydroquinone 4% (HQ4%, Hydroquinona 40 mg/g, Germed, Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Other: Liftactiv® B3 Serum
In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
Other: Liftactiv® B3 retinol night cream
In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
Other: Sunscreen UVAage® Inter SPF 50+
twice daily (morning and beginning of the afternoon)
Other: Mineral 89 cream
2 drops in the morning before sunscreen application for 6 months
Active Comparator: Group 3
Combination of hydroquinone, resorcinol corticosteroid (Kligman Trio, Vitacid Plus Cream, Claredor Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Other: Liftactiv® B3 Serum
In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
Other: Liftactiv® B3 retinol night cream
In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
Other: Sunscreen UVAage® Inter SPF 50+
twice daily (morning and beginning of the afternoon)
Other: Mineral 89 cream
2 drops in the morning before sunscreen application for 6 months

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
antipigmenting assessment
Time Frame: Day 84
Melasma Area Severity Index (MASI)
Day 84
antipigmenting assessment
Time Frame: Day 84
modified Melasma Area Severity Index (mMASI)
Day 84
antipigmenting assessment
Time Frame: Day 168
Melasma Area Severity Index(MASI)
Day 168
antipigmenting assessment
Time Frame: Day 168
modified Melasma Area Severity Index (mMASI)
Day 168

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
antipigmenting assessment
Time Frame: Day-28
Melasma Area Severity Index(MASI)
Day-28
antipigmenting assessment
Time Frame: Day-28
modified Melasma Area Severity Index (mMASI)
Day-28
antipigmenting assessment
Time Frame: baseline
Melasma Area Severity Index(MASI)
baseline
antipigmenting assessment
Time Frame: baseline
modified Melasma Area Severity Index (mMASI)
baseline
antipigmenting assessment
Time Frame: Day 28
Melasma Area Severity Index(MASI)
Day 28
antipigmenting assessment
Time Frame: Day 28
modified Melasma Area Severity Index (mMASI)
Day 28
antipigmenting assessment
Time Frame: Day 56
Melasma Area Severity Index(MASI)
Day 56
antipigmenting assessment
Time Frame: Day 56
modified Melasma Area Severity Index (mMASI)
Day 56
antipigmenting assessment
Time Frame: Day 112
Melasma Area Severity Index(MASI)
Day 112
antipigmenting assessment
Time Frame: Day 112
modified Melasma Area Severity Index (mMASI)
Day 112
antipigmenting assessment
Time Frame: Day 140
Melasma Area Severity Index(MASI)
Day 140
antipigmenting assessment
Time Frame: Day 140
modified Melasma Area Severity Index (mMASI)
Day 140
Investigator Global Assessment (IGA) assessment
Time Frame: Day -28
IGA score
Day -28
Investigator Global Assessment (IGA) assessment
Time Frame: baseline
IGA score
baseline
Investigator Global Assessment (IGA) assessment
Time Frame: Day 28
IGA score
Day 28
Investigator Global Assessment (IGA) assessment
Time Frame: Day 56
IGA score
Day 56
Investigator Global Assessment (IGA) assessment
Time Frame: Day 84
IGA score
Day 84
Investigator Global Assessment (IGA) assessment
Time Frame: Day 112
IGA score
Day 112
Investigator Global Assessment (IGA) assessment
Time Frame: Day 140
IGA score
Day 140
Investigator Global Assessment (IGA) assessment
Time Frame: Day 168
IGA score
Day 168
Clinical assessment (fine lines, skin tone, radiance, texture and elasticity)
Time Frame: Day -28
scores 0 to 5
Day -28
Clinical assessment (fine lines, skin tone, radiance, texture and elasticity)
Time Frame: baseline
scores 0 to 5
baseline
Clinical assessment (fine lines, skin tone, radiance, texture and elasticity)
Time Frame: Day 28
scores 0 to 5
Day 28
Clinical assessment (fine lines, skin tone, radiance, texture and elasticity)
Time Frame: Day 84
scores 0 to 5
Day 84
Clinical assessment (fine lines, skin tone, radiance, texture and elasticity)
Time Frame: Day 168
scores 0 to 5
Day 168
Clinical scoring hyperpigmentation
Time Frame: baseline
scale 0 to 10
baseline
Clinical scoring hyperpigmentation
Time Frame: Day 28
scale 0 to 10
Day 28
Clinical scoring hyperpigmentation
Time Frame: Day 56
scale 0 to 10
Day 56
Clinical scoring hyperpigmentation
Time Frame: Day 84
scale 0 to 10
Day 84
Clinical scoring hyperpigmentation
Time Frame: Day 112
scale 0 to 10
Day 112
Clinical scoring hyperpigmentation
Time Frame: Day 140
scale 0 to 10
Day 140
Clinical scoring hyperpigmentation
Time Frame: Day 168
scale 0 to 10
Day 168
Clinical scoring target lesion comparing to surrounding skin
Time Frame: baseline
scale 0 to 10
baseline
Clinical scoring target lesion comparing to surrounding skin
Time Frame: Day 28
scale 0 to 10
Day 28
Clinical scoring target lesion comparing to surrounding skin
Time Frame: Day 56
scale 0 to 10
Day 56
Clinical scoring target lesion comparing to surrounding skin
Time Frame: Day 84
scale 0 to 10
Day 84
Clinical scoring target lesion comparing to surrounding skin
Time Frame: Day 112
scale 0 to 10
Day 112
Clinical scoring target lesion comparing to surrounding skin
Time Frame: Day 140
scale 0 to 10
Day 140
Clinical scoring target lesion comparing to surrounding skin
Time Frame: Day 168
scale 0 to 10
Day 168
Subject global efficay rating
Time Frame: Day 28
rating
Day 28
Subject global efficay rating
Time Frame: Day 56
rating
Day 56
Subject global efficay rating
Time Frame: Day 84
rating
Day 84
Subject global efficay rating
Time Frame: Day 112
rating
Day 112
Subject global efficay rating
Time Frame: Day 140
rating
Day 140
Subject global efficay rating
Time Frame: Day 168
rating
Day 168
Investigator global efficay rating
Time Frame: Day 28
rating
Day 28
Investigator global efficay rating
Time Frame: Day 56
rating
Day 56
Investigator global efficay rating
Time Frame: Day 84
rating
Day 84
Investigator global efficay rating
Time Frame: Day 112
rating
Day 112
Investigator global efficay rating
Time Frame: Day 140
rating
Day 140
Investigator global efficay rating
Time Frame: Day 168
rating
Day 168
Cosmetic acceptability
Time Frame: Day 28
questionnaire
Day 28
Cosmetic acceptability
Time Frame: Day 56
questionnaire
Day 56
Cosmetic acceptability
Time Frame: Day 84
questionnaire
Day 84
Cosmetic acceptability
Time Frame: Day 112
questionnaire
Day 112
Cosmetic acceptability
Time Frame: Day 140
questionnaire
Day 140
Cosmetic acceptability
Time Frame: Day 168
questionnaire
Day 168
Evolution of quality of life
Time Frame: Day -28
MelasQoL
Day -28
Evolution of quality of life
Time Frame: baseline
MelasQoL
baseline
Evolution of quality of life
Time Frame: Day 28
MelasQoL
Day 28
Evolution of quality of life
Time Frame: Day 56
MelasQoL
Day 56
Evolution of quality of life
Time Frame: Day 84
MelasQoL
Day 84
Evolution of quality of life
Time Frame: Day 112
MelasQoL
Day 112
Evolution of quality of life
Time Frame: Day 140
MelasQoL
Day 140
Evolution of quality of life
Time Frame: Day 156
MelasQoL
Day 156
images
Time Frame: baseline
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
baseline
images
Time Frame: Day 28
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
Day 28
images
Time Frame: Day 56
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
Day 56
images
Time Frame: Day 84
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
Day 84
images
Time Frame: Day 112
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
Day 112
images
Time Frame: Day 140
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
Day 140
images
Time Frame: Day 168
Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.
Day 168
Skin quality
Time Frame: baseline
Chromameter, Individual Typology Angle (ITA)
baseline
Skin quality
Time Frame: Day 28
Chromameter, Individual Typology Angle (ITA)
Day 28
Skin quality
Time Frame: Day 56
Chromameter, Individual Typology Angle (ITA)
Day 56
Skin quality
Time Frame: Day 84
Chromameter, Individual Typology Angle (ITA)
Day 84
Skin quality
Time Frame: Day 112
Chromameter, Individual Typology Angle (ITA)
Day 112
Skin quality
Time Frame: Day 140
Chromameter, Individual Typology Angle (ITA)
Day 140
Skin quality
Time Frame: Day 168
Chromameter, Individual Typology Angle (ITA)
Day 168
transepidermal water loss
Time Frame: baseline
Tewameter
baseline
transepidermal water loss
Time Frame: Day 28
Tewameter
Day 28
transepidermal water loss
Time Frame: Day 56
Tewameter
Day 56
transepidermal water loss
Time Frame: Day 84
Tewameter
Day 84
transepidermal water loss
Time Frame: Day 112
Tewameter
Day 112
transepidermal water loss
Time Frame: Day 140
Tewameter
Day 140
transepidermal water loss
Time Frame: Day 168
Tewameter
Day 168
skin hydration
Time Frame: baseline
Corneometer
baseline
skin hydration
Time Frame: Day 28
Corneometer
Day 28
skin hydration
Time Frame: Day 56
Corneometer
Day 56
skin hydration
Time Frame: Day 84
Corneometer
Day 84
skin hydration
Time Frame: Day 112
Corneometer
Day 112
skin hydration
Time Frame: Day 140
Corneometer
Day 140
skin hydration
Time Frame: Day 168
Corneometer
Day 168
confocal
Time Frame: baseline
confocal measurements (15 subjects)
baseline
confocal
Time Frame: Day 84
confocal measurements (15 subjects)
Day 84
confocal
Time Frame: Day 168
confocal measurements (15 subjects)
Day 168
exposome questionnaire
Time Frame: baseline
questionnaire
baseline
Melasma status
Time Frame: baseline
questionnaire
baseline
adverse events
Time Frame: baseline
reporting
baseline
adverse events
Time Frame: Day 28
reporting
Day 28
adverse events
Time Frame: Day 56
reporting
Day 56
adverse events
Time Frame: Day 84
reporting
Day 84
adverse events
Time Frame: Day 112
reporting
Day 112
adverse events
Time Frame: Day 140
reporting
Day 140
adverse events
Time Frame: Day 168
reporting
Day 168

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cosmetique Active International

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Claire Deloche-Bensmain, PhD, La Roche Posayl Laboratoires Dermatologiques

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 15, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 31, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 31, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 7, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 18, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 23, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 23, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 18, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • VCY23-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

the protocol will be shared by the sponsor upon reasonable request for one year after the end of the study

IPD Sharing Time Frame

one after finishing study

IPD Sharing Access Criteria

upon request to the sponsor

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings